TY - JOUR
T1 - Target-selective degradation of proteins and oligosaccharides by light-activated hybrid molecules for molecular-targeted photodynamic therapy
AU - Toshima, Kazunobu
PY - 2009/9/1
Y1 - 2009/9/1
N2 - Proteins and oligosaccharides are key players in many biological events. The development of novel methods for the selective degradation of targeted proteins and oligosaccharides has attracted much attention in the fields of chemistry, biology and medicine. Target-selective degradations of proteins, such as estrogen receptor-α androgen receptor and HIV-1 protease, by light-activated 2-phenylquinoline-steroid hormone hybrids, porphyrin derivatives and fullerene-sugar hybrids, and target-selective degradation of oligosaccharides, such as a T-antigen disaccharide, by a light-activated anthraquinone-lectin hybrid have been achieved. This novel class of light-activated and molecular-targeted molecules, namely molecular-targeted photosensitizers, promise bright prospects for finding not only molecular-targeted bioprobes for future application in the life sciences but also molecular-targeted drugs for future photodynamic therapy.
AB - Proteins and oligosaccharides are key players in many biological events. The development of novel methods for the selective degradation of targeted proteins and oligosaccharides has attracted much attention in the fields of chemistry, biology and medicine. Target-selective degradations of proteins, such as estrogen receptor-α androgen receptor and HIV-1 protease, by light-activated 2-phenylquinoline-steroid hormone hybrids, porphyrin derivatives and fullerene-sugar hybrids, and target-selective degradation of oligosaccharides, such as a T-antigen disaccharide, by a light-activated anthraquinone-lectin hybrid have been achieved. This novel class of light-activated and molecular-targeted molecules, namely molecular-targeted photosensitizers, promise bright prospects for finding not only molecular-targeted bioprobes for future application in the life sciences but also molecular-targeted drugs for future photodynamic therapy.
UR - http://www.scopus.com/inward/record.url?scp=77953383906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953383906&partnerID=8YFLogxK
U2 - 10.4155/fmc.09.81
DO - 10.4155/fmc.09.81
M3 - Review article
C2 - 21425996
AN - SCOPUS:77953383906
VL - 1
SP - 1113
EP - 1124
JO - Future Medicinal Chemistry
JF - Future Medicinal Chemistry
SN - 1756-8919
IS - 6
ER -